(PRESS RELEASE) HERZLIYA, ISRAEL — Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the U.S., evaluating its novel eye drop candidate designed to improve near vision for people with presbyopia.
“We are excited to move into the final stage of clinical development of our corrective eye drop while preparing for pre-commercialization,” said Elad Kedar, CEO of Orasis. “Presbyopia, the inability to focus on near objects, is a progressive, ubiquitous condition that affects almost two billion people above the age of 40 all around the world. Orasis is committed to making near vision clear again for people who live with this condition. Our proprietary eye drop formulation was designed to achieve the optimal balance between efficacy, safety, and comfort. Promising results from our well powered Phase 2b study, along with the recent Series C funding, have paved a promising path for us to advance our product candidate through Phase 3 development and pre-commercialization efforts. We look forward to providing this novel and non-invasive option for presbyopia to eyecare providers and patients.”
The NEAR-1 and NEAR-2 Phase 3 studies are multi-center, double-masked, parallel-group clinical trials in the U.S. enrolling approximately 600 participants with presbyopia to further evaluate the efficacy and safety of Orasis’ eye drop candidate. For more information about the studies, visit NEAR-1 and NEAR-2.
